The collaboration agreement will enable EDX Medical and Thermo Fisher to jointly develop and potentially commercialise a number of proprietary qPCR assays - including novel and innovative cancer diagnostic solutions
EDX Medical Group develops innovative digital diagnostic products and services. (Credit: Testalize.me on Unsplash)
EDX Medical Group (“EDX Medical”), a developer of innovative digital diagnostic products and services for personalised treatment of cancer, heart disease and infectious diseases, today announced it has entered into a collaborative agreement with Thermo Fisher Scientific EMEA Ltd. (“Thermo Fisher”) the world leader in serving science and supplier of analytical instruments, life sciences solutions, specialty diagnostics, laboratory, pharmaceutical and biotechnology services.
The collaboration agreement will enable EDX Medical and Thermo Fisher to jointly develop and potentially commercialise a number of proprietary qPCR assays – including novel and innovative cancer diagnostic solutions.
The multi project collaboration will harness Thermo Fisher’s powerful technologies and information translation systems to deliver a number of advanced testing solutions in development at EDX or licensed from partners, including a proprietary assay to enable personalised radiotherapy and a novel chemotherapy toxicity assay focusing on serious adverse events.
Source: Company Press Release